• Title/Summary/Keyword: 두경부암 환자

Search Result 209, Processing Time 0.028 seconds

Comparison and Evaluation of radiotherapy plans by multi leaf collimator types of Linear accelerator (선형가속기의 다엽콜리메이터 형태에 따른 치료계획 비교 평가)

  • Lim, Ji Hye;Chang, Nam Joon;Seok, Jin Yong;Jung, Yun Ju;Won, Hui Su;Jung, Hae Youn;Choi, Byeong Don
    • The Journal of Korean Society for Radiation Therapy
    • /
    • v.30 no.1_2
    • /
    • pp.129-138
    • /
    • 2018
  • Purpose : An aim of this study was to compare the effect of multi leaf collimator(MLC) types for high dimension radiotherapy in treatment sites used clinically. Material and Method : 70 patients with lung cancer, spine cancer, prostate cancer, whole pelvis, head and neck, breast cancer were included in this study. High definition(HD) MLC of TrueBeam STx (Varian Medical system, Palo Alto, CA) and millenium(M) MLC of VitalBeam (Varian Medical system, Palo Alto, CA) were used. Radiotherapy plans were performed for each patient under same treatment goals with Eclipse (Version 13.7, Varian Palo Alto USA, CA). To compare the indicators of the radiotherapy plans, planning target volume(PTV) coverage, conformity index(CI), homogeneity index(HI), and clinical indicators for each treatment sites in normal tissues were evaluated. To evaluate low dose distribution, $V_{30%}$ values were compared according to MLC types. Additionally, length and volume of targets for each treatment sites were investigated. Result : In stereotatictic body radiotherapy(SBRT) plan for lung, the average value of PTV coverage was reduced by 0.52 % with HD MLC. With SBRT plan using HD MLC for spine, the average value of PTV coverage decreased by 0.63 % and maximum dose decreased by 1.13 %. In the test of CI and HI, the values in SBRT plan with HD MLC for spine were 1.144, 1.079 and the values using M MLC were 1.160, 1.092 in SBRT plan for lung, The dose evaluation of critical organ was reduced by 1.48 % in the ipsilateral lung mean dose with HD MLC. In prostate cancer volumetric modulated arc therapy(VMAT) with HD MLC, the mean dose and the $V_{30}$ of bladder and the mean dose and the $V_{25}$ of rectum were reduced by 0.53 %, 1.42 %, 0.97 %, and 0.69 %, respectively (p<0.05). The average value of heart mean dose was reduced by 0.83 % in breast cancer VMAT with M MLC. Other assessment indices for treatment sites showed no significant difference between treatment plans with two types of MLC. Conclusion : Using HD MLC had a positive impact on the PTV coverage and normal tissue sparing in usually short or small targets such as lung and spine SBRT and prostate VMAT. But, there was no significant difference in targets with long and large such as lung, head and neck, and whole pelvis for VMAT.

  • PDF

두경부암의 6MV 광자선 치료 시 표면선량 증가를 위한 Spoiler의 유용성 평가

  • 이강혁;김원택;이화중;김대영
    • The Journal of Korean Society for Radiation Therapy
    • /
    • v.14 no.1
    • /
    • pp.41-47
    • /
    • 2002
  • 1.목적 두경부암(head and neck Ca)과 쇄골상부(Supraclavicular)에 6MV 광자선으로 치료 시 치료부위(Target volume)가 피부에서 대략 $1^{\sim}2mm$정도 깊이에 위치할 경우, 6MV 광자선의 선량분포는 표면선량이 낮아서 치료에 적합하지 않기 때문에 Bolus와 같이 사용하지만 Skin Sparing(피부보호)효과의 손실로 피부의 손상이 발생할 수 있다. 이러한 이유로 피부의 보호와 치료 시 표면선량의 증가를 위해 Spoiler(산란판)를 제작하여 측정 후 그 특성을 이해하고 선량의 분포를 통하여 Bolus와 비교한 후에 Spoiler의 유용성에 대해 평가하고자 하였다. 2.방법 Siemens사 선형가속기(PRIMUS)의 6MV 광자선을 사용하여 Spoiler의 사용여부 및 Spoiler의 사용 시에는 조사면의 크기를 $5{\times}5,\;7{\times}7,\;10{\times}10,\;15{\times}15,\;20{\times}20cm^2$로 하고 Spoiler와 표면과의 거리는 6, 10, 15cm로 바꾸어 가면서 물팬톰(PTW. 독일)을 이용해 깊이와 측방에 따른 선량분포를 Markus 전리함(PTW. 독일)으로 측정하였으며 전리함의 방수를 위해 씌어진 방수 캡 때문에 표면선량을 별도의 고형 팬톰으로 측정하였다. 표면의 측정선량은 전리함의 측면 벽 등에 의한 선량 측정치의 증가 현상으로 과 반응을 보였으며 이를 교정하였다. 그리고 측정된 데이터를 치료계획 시스템(Pinnacle 6.0m)으로 비교, 분석하였다. 3.결과 Spoiler의 사용 시 3cm깊이 측정선량 백분율과 Spoiler를 사용하지 않은 해당 치료 조사면의 3cm깊이 선량의 백분율에 일치하도록 하여 가상의 치료 깊이인 2mm에서 측정값을 비교하여 본 결과 조사면 $5{\times}5,\;10{\times}10,\;20{\times}20cm^2$에서 OPEN시 62, 64, $70\%$, Bolus는 97, 97, $99\%$로 Spoiler의 사용 시 표면과의 거리가 6cm에서 82, 98, $103\%$, 10cm에는 72, 89, $101\%$, 15m에 65, 79, $96\%$로 나타났으며 표면에서의 측정값을 비교하여 본 결과 OPEN시 11, 17, $27\%$, Bolus는 84, 84, $86\%$, Spoiler의 사용 시 6cm에서 40, 71, $93\%$, 10cm에는 25, 50, $81\%$, 15cm에 18, 36, $67\%$를 나타내었다. 또한 3m깊이에서의 측방 선량분포에서 Spoiler의 거리변화(6, 10cm)는 심부선량의 변화에 영향을 주지 않는 것으로 확인할 수 있었다. 그리고 위의 실험측정치를 치료계획 시스템에 입력하여 선량분포를 확인한 결과 Spoiler를 사용하는 경우 OPEN에 비해 선량분포 영역을 표면으로 끌어 올릴 수 있으며 Bolus 보다 피부 보호효과는 어느 정도 유지가 되는 것을 보여주었다. 4.결론 이와 같이 Spoiler는 Bolus와 비교하여 6MV 광자선의 build up 영역을 표면으로 증가시키는 동시에 Skin Sparing(피부보호)효과를 유지할 수 있으며 두경부암의 치료에서 Spoiler의 사용이 가능한 조건으로는 조사면이 $5{\times}5cm^2$에서 Spoiler와 표면과의 거리가 6cm일 때, $7{\times}7cm^2$에서 6cm, 10cm였고 $10{\times}10cm^2$는 10cm, 15cm로, $15{\times}15cm^2$는 15cm의 간격으로 평가되었다. 또한 $20{\times}20cm^2$의 조사면, Spoiler가 6cm 간격 인 경우 Bolus를 사용한 것 보다 더욱 높은 표면선량을 나타내었다. 그러나 Spoiler와 표면간의 거리를 다르게 함으로써 깊이에 따라 선량분포를 다양하게 나타낼 수 있기 때문에 표면선량의 증가와 피부의 보호를 위해 환자의 피부 두께, 실제 치료 부위의 깊이 등을 고려한다면 Spoiler를 사용하는 것이 bolus를 사용하는 것보다 더 유용하게 적용할 수 있을 것으로 사료된다.

  • PDF

Clinical Study on Laryngeal Cancer (후두암의 임상적 연구)

  • 문교갑;최종일;박철원;이형석;안경성
    • Proceedings of the KOR-BRONCHOESO Conference
    • /
    • 1993.05a
    • /
    • pp.105-105
    • /
    • 1993
  • Laryngeal cancer is the commonest of all head and neck malignancies and, in Korea, constitutes approximately 2.3% of all malignancies among males. Survival rate is rather higher than any other head and neck malignancies. Treatment results of 121 laryngeal cancer patients were analyzed. 1. Glottic region 44%, supraglottic 41%, subglottic 8%, transglottic 7%. 2. Rate of cervical metastasis according to T stage was 19% in T2 stage, 47% in T3 stage, 69% in T4 stage. 3. Overall 3-year NED survival rate was 65% and showed stage I 93%, stage II 76%, stage III 63%, stage IV 53%. 4. Glottic cancer showed much better prognosis(3-year NED 82%) than supraglottic cancer(3-year NED 58 %). 5. According to treatment modality, complication rates in surgery with postoperative radiation was higher than in surgery along and disproportionally higher in salvage surgery after failed curative radiation.

  • PDF

Efficacy and Safety of $Ultracet^{(R)}$ in Ambulatory Patients with Cancer Pain (암환자의 통증치료에 대한 $Ultracet^{(R)}$의 유효성과 안전성)

  • Lee, Hyo-Jin;Jin, Sun-Ah;Yun, Gak-Won;Yang, Yung-Joon;Park, Nam-Whan;Chun, Jae-Min;Park, Nam-Sook;Yun, Hwan-Jung;Jo, Deog-Yeon;Kim, Sam-Yong
    • Journal of Hospice and Palliative Care
    • /
    • v.9 no.2
    • /
    • pp.101-105
    • /
    • 2006
  • Purpose: We aimed to investigate the efficacy and side effects of $Ultracet^{(R)}$ in relieving cancer pain in setting. Methods: Sixty-one cancer patients over 18 years old, who had cancer pain with or without medication, were enrolled. Pain and other variables were evaluated before and after treatment with $Ultracet^{(R)}$ for 2 weeks, using Korean version of Brief Pain Inventory. Results: Of 61 patients with assessable efficacy data, the maximum pain intensity(PI) experienced in a day were $5.18{\pm}1.41\;and\;4.82{\pm}1.94$, before and after treatment with$Ultracet^{(R)}$ respectively (P=0.113). The minimum PI experienced in a day were $1.2{\pm}1.05\;and\;0.87{\pm}1.35$, before and after treatment with $Ultracet^{(R)}$, respectively (P=0.038). The average PI experienced in a day were $3.61{\pm}1.01\;and\;3.15{\pm}1.73$, before and after treatment with $Ultracet^{(R)}$, respectively (P=0.022). The current PI were $3.63{\pm}1.25\;and\;2.85{\pm}1.94$, before and after treatment with $Ultracet^{(R)}$, respectively (P=0.003). Regarding the quality of life, only mood changed for the better in 49 patients who were treated with $Ultracet^{(R)}$ alone ($1.98{\pm}1.73\;and\;1.35{\pm}1.15$, before and after treatment respectively; P=0.046). There were five (8.2%) adverse events associated with $Ultracet^{(R)}$ treatment. Conclusion: $Ultracet^{(R)}$ seems effective and safe in ambulatory patients with cancer pain.

  • PDF

Comparison between Surgical and Non-Surgical Treatment of Squamous Cell Carcinoma of Tonsil:Retrospective Analysis of 87 Patients (편도 편평상피암의 수술적 치료와 비수술적 치료의 비교:87명 환자의 후향적 분석)

  • Koo, Dong-Hoe;Lee, Sang-Wook;Song, Si-Yeol;Kim, Sang-Yoon;Nam, Soon-Yuhl;Choi, Seung-Ho;Roh, Jong-Lyel;Cho, Kyung-Ja;Ahn, Jin-Hee;Kim, Sung-Bae
    • Korean Journal of Head & Neck Oncology
    • /
    • v.23 no.1
    • /
    • pp.3-8
    • /
    • 2007
  • 연구목적:국소적 진행성 편도암환자에서 수술적치료와 비수술적치료의 결과를 비교 분석하고자 하였다. 연구방법 : 수술 후 보조방사선요법을 시행한 군과 유도화학요법 시행 유무에 상관없이 근치적 방사선 치료 또는 항암화학-방사선 동시치료를 받은 비수술군의 임상결과를 후향적으로 분석하였다. 연구결과:52.4개월의 중앙 추적기간결과, 대상환자의 중앙 연령은 53세 이었다. 대상 환자 중 병기 Ⅲ, Ⅳ기 환자는 72명(82.8%)이었고, 49명(56.3%)이 수술적 치료를, 38명(43.7%)명이 비수술적 치료를 받았다. 방사선 조사량외에 양군간의 차이는 없었다 (수술군:60.4Gy, 비수술군:70.2Gy, p=0.02). 비수술군의 전체 생존율은 81.6%이었다. 수술군의 8명(16.3%), 비수술군의 6명 (15.8%)에서 재발이 발생하였다. 흥미로운 사실은 원격재발은 2명 모두 수술군에서 발생하였다. 병기 III, IV기의 5년 무병생존율과 전체생존율은 수술군이 각각 82.1%, 86.9%이고, 비수술군이 각각 83.3%, 83.1%이었다(p=0.96, p=0.96). 결론:수술적 치료에 비해 비수술적 치료가 활동능력이 불량한 환자에게 선호되었을 가능성이 있었음에도 불구하고, 치료성적은 비슷하였다. 편도암에서 수술적 치료와 비수술적 치료의 전향적 무작위 비교연구가 필요하다.

Neck metastasis of invasive ductal carcinoma of breast causing voice change: a case report (음성변화를 주증상으로 내원한 유방암의 경부연조직 전이환자 1례)

  • Lee, Hyung Min;Park, Ji hoon;Kim, Jin Hwan;Kim, Jung Won;Lee, Dong Jin
    • Korean Journal of Head & Neck Oncology
    • /
    • v.33 no.2
    • /
    • pp.67-70
    • /
    • 2017
  • We present a metastatic carcinoma from the breast to the neck soft tissue around common carotid artery, with a rare finding of voice change. A 60 year-old female patient presented with voice change for 7 months. Neck ultrasound revealed a soft tissue mass between internal jugular vein and common carotid artery. Result of fine needle aspiration biopsy was a metastatic carcinoma. Computed tomography and magnetic resonance image revealed $2.5{\times}3.0cm$ sized irregular marginated soft tissue mass in right lower neck encasing common carotid artery and internal jugular vein. Surgical resection was performed and pathologic result with immunohistochemical analysis confirmed the diagnosis of a metastatic invasive ductal carcinoma originated from breast.

How we should approach and manage older patients with cancer (노인 암 환자의 접근과 관리 원칙)

  • Kim, Jee Hyun
    • Korean Journal of Head & Neck Oncology
    • /
    • v.33 no.2
    • /
    • pp.1-8
    • /
    • 2017
  • Cancer is the disease of aging and Korea is one of the fastest aging country in the world. Older patients have decreased organ function and stress tolerance, therefore are at high risk of functional decline and developing complication from cancer and cancer treatment. Before beginning cancer treatment, it is important to assess patients' life expectancy, whether the patient is likely to die of cancer or of other comorbidity, and also the risks with cancer treatment. In order to estimate patient's physiologic age, it is recommended to perform geriatric assessment and implement appropriate geriatric intervention together with meticulous supportive care, when planning cancer treatment for older patients. In a resource limited country such as Korea, two step approach of applying screening tool followed by geriatric assessment can be more efficient. Geriatric assessment is used to predict toxicity from cancer treatment such as surgery, radiotherapy, and chemotherapy, predict survival, and also to aid treatment decision. Number of randomized trials are ongoing to compare usual care versus oncogeriatric care, and with these results we expect to improve outcome of older patients with cancer.

A Case of Tracheal Reconstruction with Sternohyoid Muscle Flap in Papillary Thyroid Carcinoma Invading Trachea (기관을 침범한 유두상 갑상선 암 환자에서 흉설골근을 통한 기관재건술 1예)

  • Wu, Hee Won;Kim, Yeon Soo;Shin, YooSeob;Kim, Chul-Ho
    • Korean Journal of Head & Neck Oncology
    • /
    • v.30 no.2
    • /
    • pp.115-118
    • /
    • 2014
  • Papillary thyroid carcinoma is known as its relatively high cure rate after surgical treatment. But invasion of the trachea by thyroid carcinoma is poor prognostic factor and the best management is en bloc surgical resection of the tumor invading the trachea. A 55-year-old man was diagnosed as papillary thyroid cancer with tracheal invasion. We treated the patient by total thyroidectomy with window resection of invading trachea followed by immediate reconstruction with sternohyoid muscle flap and tracheostomy. At 48 days after surgery, tracheostoma was closed and the patient had no functional complication by the surgical process. Until 10 months after surgery, there was no sign of recurrence and the patient led social life without any discomfort. We present this case with a review of the related literatures.

A case of tracheal cancer with thyroid invasion (갑상선을 침범한 기관암 환자 1례)

  • Lim, Kang Hyeon;Jeong, Yong Jun;Han, Mun Soo;Lee, Ju Han;Kim, Young Sik;Oh, Kyung Ho;Kwon, Soon Young
    • Korean Journal of Head & Neck Oncology
    • /
    • v.34 no.2
    • /
    • pp.61-64
    • /
    • 2018
  • Malignant lesion of the trachea predominantly results from direct spread of adjacent tumors, whereas primary tracheal malignancies are rarely observed. Tracheal tumors are usually diagnosed late on account of delayed specific symptoms: dyspnea, stridor, coughing and hemoptysis. Primary tracheal tumors, although very rare, may extend into the thyroid gland and present as a thyroid mass. Surgery, followed by adjuvant radiotherapy, is the treatment of choice. A case of primary tracheal cancer with thyroid invasion is reported, and a review of the literature is presented.

Evaluation of the Treatment Response after Hypofractionated Radiotherapy in Patients with Advanced Head and Neck Cancers (진행성 두경부 상피세포암 환자에서 소분할 방사선조사 후의 치료반응 평가)

  • Kim, Won-Taek;Ki, Yong-Kan;Nam, Ji-Ho;Kim, Dong-Hyun;Cho, Kyu-Sup;Lee, Jin-Choon;Lee, Byung-Joo;Kim, Dong-Won
    • Radiation Oncology Journal
    • /
    • v.27 no.2
    • /
    • pp.55-63
    • /
    • 2009
  • Purpose: This study was performed to objectively evaluate the rate of tumor response to hypofractionated radiotherapy for advanced squamous cell carcinomas of the head and neck. Materials and Methods: Thirty-one patients with advanced squamous cell carcinoma of the head and neck, who were treated by hypofractionated radiotherapy with 3 Gy per fraction for palliative purpose between 1998 and 2008, were reviewed retrospectively. Every tumor-volume was measured and evaluated from CT (computed tomography) images obtained before and 2~3 months after radiotherapy. The radiation toxicity was assessed during and after radiotherapy. A statistical analysis was performed to investigate overall survival, progressionfree survival, and the prognostic factors for survival and response. Results: The median age of the study patients was 70 years. In addition, 85% of the patients were in stage 4 cancer and 66.7% had an ECOG performance status of 1~2. The mean tumor-volume was 128.4 cc. Radiotherapy was administered with a total dose of 24~45 Gy (median: 36 Gy) over 10~25 days. Twenty-nine patients were treated with 30 Gy or more. The observed complete response rate was 12.9% and the partial response rate was 61.3%. Median survival time was 8.9 months and the 1-year progression-free survival rate was 12.9%. The treatment response rate was confirmed as a prognostic factor in the rate of survival. The primary site, stage, tumor-volume, radiotherapy field and overall radiation-dose showed a significant relationship with survival and treatment response. No grade 4 toxicity was observed during and after radiotherapy. Conclusion: There was an objective tumor-regression in about 74% of patients treated by hypofractionated radiotherapy. Further evaluation is needed to select the appropriate fraction-size and patient who may require the additional radiotherapy.